The Adherence of Proactive Sleep Apnea Therapy

Recruiting now · Not applicable

Conditions studied: Obstructive Sleep Apnea

In brief

The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP) therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it aims to answer are: 1. To compare the adherence of proactive therapy and conventional Automatic-PAP (APAP) therapy short-term (3 months) and long-term (12 months) for newly diagnosed OSA patients. 2. To compare health outcomes (AHI, nightly usage, leak, and patient-reported outcomes) between proactive therapy and conventional APAP therapy.

Key facts

Study ID

NCT06319482

Run by

NovaResp Technologies Inc

People needed

200

Starts

2024-06-16

Expected to finish

2025-06-16

Last updated by the study team

2024-10-04

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have a new diagnosis of moderate or severe OSA (i.e., AHI > 15 events/hour).
• Must be 18-70 years old.
• No history of self-reported, uncontrolled, severe cardiovascular or neurological issues.
• Must be able to comply with all study requirements as outlined in the consent form.
• Must be able to follow the directions of the study doctor and research team.
• Must be able to understand English and be willing to provide informed consent.

You may not qualify if…

• Prior use of PAP machines.
• Subjects actively using bi-level PAP or require oxygen therapy.
• Subjects who are medically complicated or who are medically unstable ( i.e., cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness).
• Potential sleep apnea complications that, in the opinion of the clinician, may affect the health and safety of the participant.
• Inability or unwillingness to given written informed consent.
• Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, New York Heart Association class III or IV heart failure, recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months), persistent uncontrolled hypertension despite medication use, active psychiatric disease, and coexisting non-respiratory sleep disorders that would confound functional sleep assessment.
• Pregnancy, planning to attempt to become pregnant, or breastfeeding.

Where it is running

• NovaResp Technologies Inc. — Halifax, Nova Scotia, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.